Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs) Abstract #1734

Introduction: CLARINET trial has proven the antiproliferative effects of LAN in patients with non-functioning gastro-entero-pNETs. However, the combination of LAN with targeted therapies is widely used in clinical practice and should be further evaluated.
Aim(s): This study evaluated the effects of LAN treatment, both alone and in combination with targeted therapies (sunitinib and everolimus), in a transgenic mouse model of pancreatic NETs (pNETs).
Materials and methods: 12-week old RIP-Tag2 mice were treated with LAN (BIM-23014 at 10 µg/kg/h minipump infusion) in combination with sunitinib (40 mg/Kg/day) or everolimus (10 mg/Kg/day) by oral gavage, in randomized groups of mice. Combination treatments started two weeks after LAN monotherapy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PhD Oriol Casanovas
Keywords: Lanreotide, pNET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2081 Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition
Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Oriol Casanovas
#2794 Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs
Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD Barbara Kiesewetter
#1196 CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)
Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Steven Libutti
Keywords: pNET, BEZ235, everolimus
#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke
#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr David Chan